Scholar Rock Holding Corporation
SRRK
Κατάταξη σε μετοχές
#3431
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Τιμή μετοχής
$41.58
Τελευταίος συγχρονισμός: 2026-10-20
Κεφαλαιοποίηση
$5.06B
Αλλαγή (1 ημέρα)
3.34%
Αλλαγή (1 έτος)
47.62%
Χώρα
US
Εμπόριο Scholar Rock Holding Corporation (SRRK)
Κατηγορία
Healthcare
Δείκτης P/S για Scholar Rock Holding Corporation (SRRK)
Δείκτης P/S στις October 2026 TTM: 0.00
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της Scholar Rock Holding Corporation, ο τρέχων δείκτης P/S (TTM) είναι 0.00. Στο τέλος του 2023, ο δείκτης ήταν 0.00.
Ιστορικό P/S για την Scholar Rock Holding Corporation από 2016 έως 2026
Δείκτης P/S στο τέλος κάθε έτους
| Έτος | P/S Ratio | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | 16.25 | -66.46% |
| 2021 | 48.47 | -49.95% |
| 2020 | 96.83 | 446.72% |
| 2019 | 17.71 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | -100.00% |
| 2016 | 732.28 | 0.00% |
Δείκτης P/S για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | P/S Ratio | Διαφορά P/S Ratio | Χώρα |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
